Published in the peer reviewed journal BMJ Open (March 2024, Vol 14, Issue 3), this paper by key members of the Arch Biopartners scientific team, led by Dr. Daniel Muruve at the University of Calgary, and their collaborators, describes the clinical highlights, outcomes and biomarker results of the study.

The results of the Phase II trial provided first-ever evidence validating Dipeptidase-1 (DPEP1) as a mediator of organ inflammation and therapeutic target in humans. In addition, LSALT peptide was well tolerated with no safety issues related to the drug.

The Phase II trial was an international, multicenter, randomized, double-blind, placebo-controlled, proof of concept study of LSALT peptide for the prevention of organ inflammation such as acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) in hospitalised patients infected with SARS-CoV-2. The exploratory, adaptive trial was initiated in the early stages of the global pandemic to ...

Published in the AAAS journal Science Advances this paper by key members of the Arch Biopartners scientific team led by Dr. Daniel Muruve at the University of Calgary, and their collaborators, demonstrated the mechanism by which DPEP-1 regulates the recruitment of leukocytes (i.e. inflammation) to the kidney following ischemia reperfusion injury, which is injury that occurs after a reduction in blood flow to the kidney. Ischemia reperfusion injury is a common cause of AKI in humans undergoing cardiac surgery or kidney transplantation.

Importantly, the study also confirmed the mechanism of action of two DPEP-1 inhibitors, the LSALT peptide (Metablok) and cilastatin that effectively protected the kidney during ischemia reperfusion injury. Both the LSALT peptide and cilastatin are protected by composition and method of use patents for AKI respectively and held by Arch Biopartners.

Publication Details

Science Advances, ...

Authors

Amanda Barry, Warunya Panmanee, Daniel J. Hassett, Latha Satish

Details

Published in Infection and Immunity, Volume 89, Number 11 – 15 October 2021
Read the full publication at ASM Journals or download the PDF

Abstract

Cutaneous thermal injuries from burns/explosives are a major cause of morbidity and mortality and represent a monumental burden on our current health care system. Injury severity is predominantly due to potentially lethal sepsis caused by multidrug-resistant (MDR) bacteria such as Pseudomonas aeruginosa (MDR-PA). Thus, there is a critical need to develop novel and effective antimicrobials for the (i) prevention, (ii) treatment, and (iii) healing of such wounds that are complicated by MDR-P. aeruginosa and other bacterial infections. AB569 is a novel bactericidal tandem consisting of acidified NaNO2 (A-NO₂–) and Na₂-EDTA. Here, we first show that AB569 acts synergistically to kill all human burn wound ...